Premium
α‐enolase: a novel autoantigen in patients with premature ovarian failure
Author(s) -
Sundblad Victoria,
Bussmann Leonardo,
Chiauzzi Violeta A.,
Pancholi Vijay,
Charreau Eduardo H.
Publication year - 2006
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.2006.02661.x
Subject(s) - premature ovarian failure , antibody , enolase , antigen , endocrinology , medicine , immunology , biology , blot , biochemistry , immunohistochemistry , gene
Summary Objective Although controversial, the presence of circulating antiovarian antibodies (AOA) may be considered a marker of autoimmune premature ovarian failure (POF). The purpose of the present work was to evaluate the presence of AOA in POF patients, and to identify a possible autoantigen in order to develop a reliable diagnostic tool that might help to determine the real prevalence of autoimmune POF. Design Non‐randomised study. Blood sampling for determination of circulating AOA. Patients One hundred and ten patients with POF and 60 normally menstruating women with no record of autoimmune diseases (controls). Measurements Presence of circulating AOA was assessed by Western‐blot, using cytosolic fraction from human ovarian homogenate as antigen. Results Twenty‐one of 110 women with POF presented circulating antibodies directed toward an antigen of approximately 50 kD. Sixty control subjects proved negative. After purification and analysis by mass spectrometry, the antigen was identified as α‐enolase. Conclusion Determination of the presence of circulating antiα‐enolase antibodies might be instrumental in identifying those patients who may present a putative defect in immunoregulation and therefore a possible autoimmune aetiolgy for POF.